Basis: Four-quarter operating cash flow / FMP quote market capitalization × 100. Source: stored company filings and market data; unavailable inputs remain N/A.
The operating cash flow yield is N/A as of 2026-10-06T17:52:55.582Z.
Calculation as of: 2026-10-06T17:52:55.582Z.
Quote observation: 2026-10-06T17:49:44.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 954f90b5803147d7e77bb33cb230df589f2ac0b2215919e8afc4fbf9605c1a4a
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
OPERATING CASH FLOW YIELD
N/A
Profound Medical Corp.
Market Cap
$222.75M
Operating Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$223.48M
Operating Cash Flow Yield
N/A
TTM Avg
14.77%
3Y Avg
14.64%
5Y Avg
14.64%
Market Cap
$216.82M
Operating Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$214.64M
Operating Cash Flow Yield
2.77%
TTM Avg
2.54%
3Y Avg
2.69%
5Y Avg
2.62%
Market Cap
$214.30M
Operating Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$232.32M
Operating Cash Flow Yield
N/A
TTM Avg
1.61%
3Y Avg
1.61%
5Y Avg
1.61%
Market Cap
$233.51M
Operating Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$234.75M
Operating Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | OPERATING CASH FLOW YIELD | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Profound Medical Corp. (PROF) | $222.75M | N/A | N/A | N/A | N/A |
| Keros Therapeutics, Inc. (KROS)vs › | $223.48M | N/A | 14.77% | 14.64% | 14.64% |
| Anbio Biotechnology Class A Ordinary Shares (NNNN)vs › | $216.82M | N/A | N/A | N/A | N/A |
| Biodesix, Inc. (BDSX)vs › | $229.55M | N/A | N/A | N/A | N/A |
| Niagen Bioscience Inc (NAGE)vs › | $214.64M | 2.77% | 2.54% | 2.69% | 2.62% |
| Lyell Immunopharma, Inc. (LYEL)vs › | $214.30M | N/A | N/A | N/A | N/A |
| MacroGenics, Inc. (MGNX)vs › | $232.32M | N/A | 1.61% | 1.61% | 1.61% |
| Nautilus Biotechnolgy, Inc. (NAUT)vs › | $233.51M | N/A | N/A | N/A | N/A |
| BioAge Labs Inc. (BIOA)vs › | $234.75M | N/A | N/A | N/A | N/A |
| InflaRx N.V. (IFRX)vs › | $235.67M | N/A | N/A | N/A | N/A |
OCF Yield = TTM Operating Cash Flow / Market Cap
Operating cash flow yield is the inverse of P/OCF, expressing trailing operating cash flow as a percentage of price. It sits between earnings yield (before non-cash accrual effects) and FCF yield (before capital expenditure).
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
